Neurocrine Biosciences | NBIX - Operating Expenses


Neurocrine Biosciences reported $577.6M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Agios Pharmaceuticals USD 141.54M 11.8M Dec/2025
ALKERMES USD 1.73B 1.44B Sep/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amgen USD 5.9B 773M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Cytokinetics USD 168.69M 9.58M Sep/2025
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Exelixis USD 362.75M 21.35M Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
Prothena USD 42.18M 14.25M Sep/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Repligen USD 176.13M 279K Sep/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
Teva Pharmaceutical Industries USD 4.22B 812M Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025
Xoma USD 22.84M 1.67M Sep/2024